For Healthcare Professionals

Candin for the Treatment of Common Warts

clipboard-pencil

About the study

The goal of this clinical trial is to compare outcome in healthy subjects 12 years of age and older with at least 3, but no more than 20, common warts (Verruca vulgaris) following treatment with Candin or placebo. The main questions it aims to answer are: * does treatment with Candin result in better clearance of warts than placebo * how many injections are required to result in wart clearance Participants will * have one wart selected for injection every two weeks until clearance * return 12 weeks after wart clearance for assessment of durability of response
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

  1. At least 3, but not more than 20 common warts (Verruca vulgaris)
  2. Willing to agree to use adequate contraception methods during the study

EXCLUSION CRITERIA

Exclusion Criteria:

  1. Systemic or localized diseases, conditions, or medications that could interfere with the assessment of safety or efficacy or that compromise immune function
  2. Candin delayed type hypersensitivity reaction test wheal sized < 5 mm or > 25 mm at the Baseline Visit
  3. History of keloid formation
  4. Prior treatment of common warts with liquid nitrogen, carbon dioxide, electrodesiccation, laser, surgery, salicylic acid, etc., that, in the Investigator's opinion, does not exhibit complete healing from the treatment
  5. Treatment with immunotherapy (e.g., diphenylcyclopropenone [DPCP], dinitrochlorobenzene [DNCB], or other), imiquimod, 5-fluorouracil, bleomycin, or podophyllin within 12 weeks of the Baseline Visit or during the study
  6. Prior treatment with Candida albicans within 12 weeks of the Baseline Visit or during the study
  7. Systemic treatment with an immunosuppressive drug during the study or in the 6 months or 5 half lives prior to the Baseline Visit or during the study (e.g., azathioprine, 6 mercaptopurine, methotrexate, infliximab, adalimumab, etanercept, systemic steroids [topical or inhaled steroids are acceptable]).
  8. Use of cantharidin or an investigational agent or device within the 30 days prior to the Baseline Visit or during the study
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 858 571-2726Email iconEmail Study Center

Study Details


Contition

Common Warts (Verruca Vulgaris)

Age

12+

Phase

PHASE3

Participants Needed

330

Est. Completion Date

Jun 30, 2025

Treatment Type

INTERVENTIONAL


Sponsor

Nielsen BioSciences, Inc.

ClinicalTrials.gov NCT Identifier

NCT05889845

Study Number

CFW-3A

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to create a personal profile and 
receive news, resources, and alerts 
about clinical trials related to your conditions of interest.